top of page
The Professional Network for Healthcare Experts
Corxel agrees $377 million SPAC combination with Amanat to fund oral obesity drug development
Corxel Pharmaceuticals US has agreed to merge with Amanat Acquisition Corp in a SPAC transaction expected to provide approximately $377 million in gross proceeds for its oral obesity drug pipeline.
nuaxia
Oct 282 min read
Novo Nordisk licenses Hengrui's once-weekly oral GLP-1/GIP candidate in deal worth up to $2.6bn
Novo Nordisk has secured rights outside Greater China to Hengrui Pharma's once-weekly oral GLP-1/GIP dual receptor agonist HRS-1596 in a deal worth up to $2.6bn.
nuaxia
Sep 302 min read
Zealand Pharma licenses GLP-1/gastrin peptide platform to Elvinix for type 1 diabetes
Zealand Pharma has licensed its GLP-1/gastrin dual-agonist peptide platform to Elvinix for development as a potentially regenerative treatment for type 1 diabetes.
nuaxia
Sep 172 min read
bottom of page